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Objectives. The aim of the present study was to test, in vivo and 
in vitro, the influence of adrenergic activation on action potential 
prolongation induced by the potassium channel blocking agent 
d-sotalol. 
Background. d-Sotalol is not effective against myocardial 
ischemia-dependent ventricular fibrillation in the presence of 
elevated sympathetic activity. Most potassium channel blockers, 
such as d-sotalol, affect only one of the two components of I k (Ikr) 
but not the other (Iks). Iks is activated by isoproterenol. An 
unopposed activation of [ks might account for the loss of anti- 
fibrillatory effect by d-sotalol in conditions of high sympathetic 
activity. 
Methods. In nine anesthetized ogs we tested at constant heart 
rate (160 to 220 beats/min) the influences of left stellate ganglion 
stimulation on the monophasic action potential prolongation 
induced by d-sotaiol. In two groups of isolated guinea pig ventric- 
ular myocytes we tested the effect of isoproterenol (10 -9 mol/liter) 
on the action potential duration at five pacing rates (from 0.5 to 
2.5 Hz) in the absence (n = 6) and in the presence (n = 8) of 
d-sotalol. 
Results. In control conditions, both in vivo and in vitro, 
adrenergic stimulation did not significantly change action poten- 
tial duration, d-Sotalol prolonged both monophasic action poten- 
tial duration in dogs and action potential duration of guinea pig 
ventricular myocytes by 19% to 24%. Adrenergie activation, either 
left stellate ganglion stimulation in vivo or isoproterenol in vitro, 
reduced by 40% to 60% the prolongation of action potential 
duration produced by d-sotalol. 
Conclusions. Sympathetic activation counteracts the effects of 
potassium channel blockers on the duration of repolarization and 
may impair their primary antifibriilatory mechanism. An intrigu- 
ing clinical implication is that potassium channel blockers may 
not offer effective protection from malignant ischemic arrhyth- 
mias that occur in a setting of elevated sympathetic activity. 
(J Am Coil Cardio11995;25:1609-14) 
The results of the Cardiac Arrhythmia Suppression Trial (1) 
and of subsequent trials (2,3) were interpreted by many as a 
message to shift from sodium to potassium channel blocking 
agents the hope for effective pharmacologic prevention of 
sudden cardiac death in patients with ischemic heart disease. 
This interpretation was largely due to the traditional assump- 
tion that the apparent efficacy of amiodarone (4,5) depends 
primarily on its effect of prolonging action potential duration 
and, hence, ventricular refractoriness. However, amiodarone is 
much more than a selective potassium channel blocker as it is 
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also a sodium and calcium channel blocker, an antiadrenergic 
agent and a coronary vasodilator (6). 
The available xperimental data on the efficacy of potas- 
sium channel blockade in preventing ischemia-induced ventric- 
ular fibrillation are not uniform, d-Sotalol (7) did not protect 
conscious dogs with a healed myocardial infarction from 
ventricular fibrillation triggered by the combination of tran- 
sient myocardial ischemia and elevated sympathetic activity 
due to physical exercise and autonomic reflexes (8). In the 
same animals adequate protection was provided by the racemic 
compound d,l-sotalol, which also possesses beta-adrenergic 
blocking activity (7). By contrast, d-sotalol showed a powerful 
antifibrillatory effect in postinfarction conscious dogs studied 
in another experimental preparation in which sympathetic 
activity is not a critical element in the genesis of lethal 
arrhythmias (9). 
The hypothesis tested in the present study is that sympa- 
thetic excitation may interfere with the mechanisms of action 
of some antiarrhythmic drugs, and specifically with potassium 
channel blockers. This concept has far-reaching theoretic and 
clinical implications and warrants adequate investigation. The 
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basis for this hypothesis tems from the evidence that the 
potassium current with the largest effect on ventricular repo- 
larization, the delayed rectifier, Ik, comprises two components: 
one rapidly activated (fkr) and one slowly activated (Iks) (10). 
Ikr is blocked by most of the currently available potassium 
channel blockers, such as d-sotalol, whereas Iks is not blocked 
by d-sotalol and is activated by isoproterenol. In conditions of 
elevated sympathetic activity Iks becomes the predominant 
component of I k (11). Thus, in the presence of enhanced 
sympathetic activity the sheer blockade of Ik~ may have a 
limited effect on action potential duration. To explore this 
concept, we performed two series of experiments in vivo and in 
vitro. The effect of potassium channel blockade was tested 
before and after sympathetic stimulation on ventricular 
monophasic action potentials in dogs, and on transmembrane 
action potentials of guinea pig isolated ventricular myocytes. 
Preliminary data have been presented (12,13). 
Methods 
In Vivo Study 
Surgical preparation. Nine healthy adult mongrel dogs (15 
to 20 kg) were anesthetized by thiopental sodium (20 mg/kg 
body weight) followed by alpha-chloralose (80 mg/kg plus 10 to 
15 mg/kg as needed). Through a left thoracotomy in the fourth 
intercostal space, the left stellate ganglion was isolated from 
the surrounding tissue and prepared for electrical stimulation. 
The pericardium was opened and the heart suspended in a 
cradle. In three dogs the sinus node was crushed to prevent the 
spontaneous sinus rate from exceeding, during adrenergic 
stimulation, the paced rate at 160 beats/min. A catheter for 
monophasic action potential recording was positioned on the 
endocardium ofthe posterior wall of the left ventricle. This site 
was chosen because it is the area primarily innervated by the 
left-sided cardiac sympathetic nerves. Plunge electrodes were 
placed in the right atrium to pace the heart. Throughout the 
experiments, arterial blood pressure, the surface lectrocardio- 
gram (ECG) and heart rate were recorded. Body temperature 
was maintained in the normal range by means of a heating pad. 
The signals were processed by custom-made direct-current 
amplifiers, digitized at a sampling rate of 1,000 Hz and fed in 
a Bard Electrophysiology computer system. Ventricular 
monophasic action potentials were recorded by means of 
bipolar pressure contact silver-silver chloride custom-built 
electrodes according to the technique described by Franz et al. 
(14). Signals were considered acceptable if their amplitude 
exceeded 15 mV. The monophasic action potential duration 
was calculated at 90% of repolarization. Each value reported 
represents he average of three measures for each experimen- 
tal condition. 
In Vitro Study 
Isolated guinea pig ventricular myocytes were obtained by 
enzymatic digestion with the use of a modification of a 
previously described method (15). Transmembrane action 
potentials were recorded by means of standard glass intracel- 
lular microelectrodes connected to a high impedance amplifier 
(Axoclamp A2, Axon Instrument). Cells were stimulated with 
0.7- to 2.5-mV square wave impulses lasting 3 to 5 ms. Action 
potential duration (APD) was measured at 80% (APD80) of 
repolarization. The duration and amplitude of the action 
potential and resting membrane potential were measured 
without knowledge of other data. 
Experimental Protocols 
In vivo. Monophasic action potentials were recorded at 
160, 180, 200 and 220 beats/min. To obtain steady state 
measurements, he baseline pacing rate was maintained for at 
least 2 rain. The left stellate ganglion was then stimulated (10 
to 15 V, 10 to 15 Hz, 3-ms pulse duration) for 20 to 30 s. Data 
were collected throughout the trial up to 30 s after the end of 
the stimulation, which was considered satisfactory if it pro- 
duced a systolic blood pressure increase of _>20 mm Hg. Ten 
minutes was allowed for recovery between each stimulation. 
The same protocol performed in control conditions was re- 
peated after intravenous bolus administration of 8 mg/kg of 
d-sotalol and again after intravenous injection of propranolol, 
0.5 mg/kg. In three dogs data could not be collected at 180 
beats/min because the spontaneous heart rate during left 
stellate ganglion stimulation exceeded the paced rate. Data 
with d-sotalol and propranolol were not collected at 220 
beats/min because of the occurrence of atrioventricular block. 
The effect of propranolol was studied in seven dogs at 180 
beats/rain and six dogs at 200 beats/min. 
In vitro. Cells were placed in the experimental chamber 
mounted on an inverted microscope (Nikon TMS Inverted 
Microscope) and continuously perfused with 1.2 mmol/liter 
calcium HEPES buffered solution. Temperature and pH were 
kept within the physiologic range throughout the study proto- 
col (pH 7.35, 37.5°C). Only rod-shaped myocytes, noncontract- 
ing, with clear striations and with physiologic resting mem- 
brane potential were studied. After cell impalement, an 
equilibration period of approximately 15min was allowed, then 
stimulation threshold was assessed and stimulation intensity 
adjusted. Cells were paced at frequencies of 0.5, 1, 1.5, 2 and 
2.5 Hz for _>50 beats. The protocol was repeated 15 min after 
the addition of isoproterenol, 10 -9 mol/liter (n = 6), or 
d-sotalol, 10 -5 tool/liter (n = 8), to the perfusion solution. The 
10-9-mol/liter isoproterenol concentration was chosen because 
it mimics the norepinephrine l vel in myocardial interstitial 
fluid (16). In the d-sotalol group the pacing protocol was 
performed a third time after 20 min of combined exposure to 
d-sotalol and isoproterenol, 10 -9 tool/liter. 
Statistical analysis. Data are presented as mean value _+ 
1 SD. Differences were tested by one-way analysis of variance 
for repeated measures (ANOVA) and Scheff6 F test (SPSS for 
Windows, SPSS Inc.). Values of p < 0.05 were considered 
statistically significant. 
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Table 1. Effect of Left Stellate Ganglion Stimulation and d-Sotalol on Monophasic Action Potential Duration In Vivo 
Monophasic Action Potential Duration (ms) AAPD90 (%) 
Pacing Rate d-Sotalol + After After d-Sotalol 
(beats/rain) Control LSGstim d-Sotalol LSGstim d-Sotalol + LSGstim 
160 (n = 3) 216 ± 28 191 ± 31 268 ± 41 234 ± 39 24% 8.3% 
180 (n = 6) 190 ± 3~ 175 ± 31 227± 42*? 205 ± 34t~ 19.5% 7.9% 
200 (n = 9) 165 ±31 152±21 197±32't  179±35t~ 19.4% 8.5% 
220 (n = 7) 158 ± 25 152 ± 22 188 ± 28't 176 ± 27"t~ 19% 11.4% 
*p < 0.01 versus control, tp < 0.01 versus left stellate ganglion stimulation (LSGstim). Sp < 0.01 versus d-sotalol. Values are expressed as mean value +_ SD. 
Statistical analysis of the data obtained at a pacing rate of 160 beats/min was not performed because of the small sample size. &APD90 = change in action potential 
duration at 90% of repolarization. 
Results 
In vivo. Nine dogs were studied at a pacing rate of 200 
beats/rain, seven at 220, six at 180 and three at 160 beats/rain. 
The results are summarized in Table 1. Sympathetic stimula- 
tion slightly reduced monophasic action potential duration by 
4% to 8% (p = NS). 
d-Sotalol increased (p < 0.01) monophasic action potential 
duration at all rates (from 24% at 160 beats/min to 19% at 220 
beats/rain). After d-sotalol, the shortening effect of left stellate 
ganglion stimulation on monophasic action potential duration 
became significant (p < 0.01). 
Most of the prolonging effect of d-sotalol on action poten- 
tial duration was lost with left stellate ganglion stimulation. 
Adrenergic activation caused aloss of 65% of the prolongation 
of monophasic action potential duration induced by d-sotalol 
at 160 beats/rain, of 62% at 180 beats/rain, of 56% at 200 
beats/min and of 39% at 220 beats/min. 
Propranolol abolished the effects of sympathetic stimula- 
tion. Monophasic action potential durations at 180 and 200 
beats/rain were, respectively, 221 + 31 and 202 + 26 ms before 
left stellate ganglion stimulation and remained 219 + 32 and 
199 + 24 ms after stimulation. 
In vitro. Isoproterenol, at the dose used in the present 
study (10 -9 tool/liter), produced minimal or no change in 
APD80 at all pacing rates (Table 2). d-Sotalol prolonged 
APD80 in all cells (n = 8, p < 0.05). The change versus control 
was +21%, +18.5%, +21%, +18%, +20% at 0.5 to 2.5 Hz 
(p < 0.05). Isoproterenol (n = 8) reduced -sotalol-induced 
APD80 prolongation by 47%, 39%, 50%, 51%, and 59% at the 
five rates tested (between 0.5 and 2.5 Hz, p < 0.05, Table 2). 
Figure 1 illustrates the similarity of the effects produced by 
d-sotalol and sympathetic activation in vivo and in vitro. It is 
quite evident how adrenergic activation greatly attenuates the 
prolongation in monophasic action potential duration and in 
action potential duration produced by d-sotalol. This phenom- 
enon is quantified in Figure 2, where the overall loss in 
prolongation of repolarization i duced by sympathetic activa- 
tion is 50% and 56%, respectively, in the in vitro and in vivo 
experimental preparations. 
Discuss ion 
The present study, through evidence obtained both in vivo 
and in vitro and in two different species, demonstrates that 
sympathetic activation reduces by half the effect of potassium 
channel blockade on the duration of ventricular repolarization. 
This finding carries several implications concerning basic car- 
diac electrophysiology, the observed failure of d-sotalol in 
preventing ischemia-induced ventricular fibrillation during ex- 
ercise in dogs after myocardial infarction (7), and the design of 
clinical trials aimed at reducing the incidence of sudden 
cardiac death. 
Basic cardiac electrophysiology. The combination of the in 
vitro and in vivo data shows that d-sotalol lengthened action 
potential duration by a similar amount, -20%, over a very 
wide range of pacing rates (from 30 to 220 beats/rain). Thus, 
d-sotalol did not show reverse use dependency (17); that is, its 
effect was not diminished at the faster heart rates. 
Table 2. Effect of Isoproterenol and d-Sotalol on Action Potential Duration In Vitro 
Action Potential Duration (ms) 
Pacing d-Sotalol + 
Rate Control Isoproterenol Control d-Sotalol Isoproterenol After 
(Hz) (n = 6) (n = 6) (n = 8) (n = 8) (n = 8) d-Sotalol 
AAPD80 (%) 
After 
d-Sotalol + 
Isoproterenol 
0.5 212 +_ 28 211 ± 37 199 + 26 241 _+ 27* 219 ± 20*? 21% 
1 200 ± 30 198 ± 40 194 + 29 230 + 27* 216 + 22*? 18.5% 
1.5 198 ± 22 200 -+ 38 191 + 28 231 +_ 28* 211 ± 18"? 21% 
2 190 + 20 195 ± 40 187 + 26 220 ± 22* 203 ± 18"] 18% 
2.5 165 + 8:~ 162 _+ 215 183 + 27 220 ± 30* 198 ± 21*t 20% 
10% 
11% 
10% 
8.5% 
8.2% 
*p < 0.05 versus control, tP < 0.05 versus d-sotalol and control. Sn = 2. &AI'D80 = change in action potential duration at 80% of repolarization. 
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Figure 1. Effect of d-sotalol and adrenergic stimulation on action 
potential duration. Top, Three left ventricular monophasic a tion 
potentials inthe same dog. Bottom, Three action potentials from the 
same guinea pig ventricular myocyte. A = control conditions; B = 
after d-sotalol (intravenous administration or addition i the perfusion 
solution); C = the effect of adrenergic stimulation (left stellate 
ganglion stimulation risoproterenol in vitro). 
The duration of repolarization was unaffected by isoproter- 
enol in vitro, whereas in vivo left stellate ganglion stimulation 
slightly shortened repolarization. The in vitro finding is not 
surprising because in two previous studies (18,19), based on 
the same isoproterenol concentration used in the present 
study, a slight prolongation of action potential duration was 
observed. The 4% to 8% reduction in monophasic action 
potential duration with stellate ganglion stimulation is consis- 
tent with the previous finding by Kuo and Surawicz (20). 
After d-sotalol, adrenergic stimulation reduced action po- 
tential duration in almost all cases. With the pure Ikr blocker 
E-4031, Sanguinetti et al. (11) observed that isoproterenol 
produced a variable response in control conditions (action 
potential duration shortening or prolongation), but that it 
always hortened action potential duration after E-4031. Inde- 
pendent of the mechanisms involved, the fact that at a longer 
action potential duration adrenergic activation ismore likely to 
result in a shortening of action potential duration, and thus of 
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Figure 2. Percent change (mean + SE) in action potential duration 
from control conditions induced by d-sotalol and by adrenergic 
stimulation. Top, Effects of left stellate ganglion stimulation (LSG 
Stim) on monophasic a tion potential innine dogs at a pacing rate of 
200 beats/min. Bottom, Changes observed ineight isolated guinea pig 
ventricular myocytes with d-sotalol and isoproterenol at a 1.5-Hz 
pacing frequency. Adrenergic stimulation reduced by 50% the action 
potential prolongation induced by d-sotalol. APD90, APD80 = action 
potential duration measured at 90% and 80% of repolarization. 
refractoriness, has obvious implications for the antiarrhythmic 
effect of potassium channel blockers. 
These considerations have to be placed in the context of the 
inability of d-sotalol to prevent lethal arrhythmias caused by 
transient myocardial ischemia during exercise in conscious 
dogs with a healed myocardial infarction (7). Indeed, protec- 
tion from ventricular fibrillation was observed in only I (10%) 
of 10 dogs treated with d-sotalol; this observation isin contrast 
to the protection of 6 (67%) of 9 of the same dogs treated with 
the racemic ompound ,l-sotalol (7). 
In the present study both the relative (i.e., the percent 
value) and the absolute prolongation achieved by d-sotalol 
were markedly attenuated bybeta-adrenergic stimulation. The 
relative prolongation ofrepolarization by d-sotalol was similar 
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in control conditions and in the sympathetic stimulated state; 
however, from the findings in the conscious dogs with a 
previous myocardial infarction (7), we now know that the 
antiarrhythmic efficacy of d-sotalol is substantially attenuated 
by sympathetic a tivation. It is reasonable topostulate that this 
failure may be due to the interaction between sympathetic 
stimulation and the so-called class III effect of d-sotalol, that is, 
the prolongation of refractoriness, which is a direct conse- 
quence of the prolongation of action potential duration. Sym- 
pathetic activation interferes with the achievement of an 
adequate prolongation of ventricular efractoriness. This is 
because the absolute value, rather than the relative change, of 
the refractory period produced by the drug best reflects its 
ability to suppress reentrant excitation. 
The results of this study may be explained according to 
• Sanguinetti et al. (11), who documented that the slow compo- 
nent of Ik, lks, not blocked by traditional potassium channel 
blockers such as d-sotalol, is enhanced by isoproterenol. In 
guinea pig ventricular myocytes at the plateau phase of a 
normal action potential, Ikr and Iks are quantitatively similar. 
Thus, blockade of Ikr alone is likely to affect only 50% of Ik. 
Given the marked effect of isoproterenol n Iks , in conditions 
of high sympathetic activity Iks may annul the effect of Ikr 
blockade on action potential duration. These results indicate 
that a correct analysis of basic cardiac electrophysiology can no 
longer ignore the importance of the interaction between 
antiarrhythmic drugs and autonomic activity. Specifically, the 
activation or block of an ionic channel may be potentiated or 
drastically reduced by autonomic mediators. 
Antifibrillatory efficacy of d-sotalol. The present findings 
help to explain the important failure of d-sotalol to prevent 
ventricular fibrillation due to acute myocardial ischemia in 
conditions of elevated sympathetic activity in conscious dogs 
with a healed myocardial infarction (7,21,22). Previous exper- 
iments in anesthetized rabbits had indicated that the action 
potential prolongation produced by d,l-sotalol gradually disap- 
pears during acute myocardial ischemia. However, d-sotalol 
prevented ventricular fibrillation in conscious dogs with a 4- to 
7-day old myocardial infarction exposed to a permanent occlu- 
sion of the left circumflex coronary artery (9). In that model 
the occlusion develops progressively due to a growing endo- 
luminal thrombus and does not elicit powerful sympathetic 
reflexes. In our own model (8), the high sympathetic activity 
and fast heart rate probably contribute to activate Iks and, to 
judge from the present findings, are likely to create a critical 
reduction of the electrophysiologic effects of d-sotalol so that 
ventricular fibrillation cannot be prevented. 
Clinical implications. The traditional design of clinical 
trials related to sudden death is based on the implicit, and 
incorrect, assumption that all enrolled patients will die because 
of the same mechanism. However, the two main mechanisms 
of death among postmyocardial infarction patients appear to 
involve either a substrate-dependent ventricular tachycardia- 
fibrillation or an ischemia-related ventricular fibrillation fa- 
vored by increases in sympathetic a tivity (23). Ik~ blockers are 
probably very effective against he first mechanism and repre- 
sent a rational choice for prevention of reentrant achy- 
arrhythmias with a short excitable gap (6). Conversely, the 
present data suggest alesser degree of protection i  conditions 
of high sympathetic a tivity. This information may be relevant 
to the design of clinical trials, such as SWORD (Survival With 
ORal D-sotalol) (24), because it suggests that potassium 
channel blockers hould be primarily tested in those patients 
more likely to die because of the first arrhythmogenic mecha- 
nism; they may be identified by the presence of a depressed left 
ventricular function and of late potentials. Conversely, it may 
be wise not to expect a large beneficial effect in those patients 
more likely to die because of the second arrhythmogenic 
mechanism; they may be identified by the presence of a 
depressed heart rate variability and baroreflex sensitivity (25). 
Such a mechanism-oriented approach to the design of clinical 
trials might avoid a situation in which the simultaneous 
inclusion of patients who may and may not be protected by the 
study drug might obscure an otherwise statistically significant 
protection, and lead to early termination of the trial (26) on 
the basis of negative results. The final goal remains the 
identification of the most appropriate herapy for each patient, 
on the basis of the most likely arrhythmogenic mechanism (6). 
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